Keeping Trust Through Health Preservation

In the year marked by the coronavirus pandemic, Hemofarm managed in the ever more demanding environment to produce and deliver medicines on time, in the required quantity and in the expected quality to the markets of Serbia and around the world, which the company considers its greatest business success in recent months. Confirmation for Hemofarm's work also came from the parent company Stada, which awarded the Serbian company within the Group for the successful functioning of the supply chain in 2020.

‘Hemofarm has confirmed its leadership position in this jubilee year, when it celebrates its 60th birthday, but above all, it has shown in action what the fight for human health means. Even in times of the greatest crises, we are expected to work smoothly and ensure a regular supply of medicines to the market. That is why, throughout the year, our goal was to provide safe working conditions for employees and to produce enough medicines for everyone - both for our citizens in Serbia and for consumers in the European Union, Russia, etc. We worked hard and I sincerely believe that our employees, together with health workers and pharmacists, were on the first line of health defense. That is why I am very grateful to all the people in Hemofam, in the production sites, in the field, as well as those who showed from their homes what we can achieve together, ’said Hemofarm CEO Dr Ronald Seeliger.

Ronald Zeliger Hemofarm

If we compare the business results in this atypical year with those achieved in 2019, Hemofarm increased the volume of production with a maintained level of 280 million packages. Namely, the volume of produced units increased by six percent, so that 6.5 billion tablets and other forms were produced in Hemofarm's plants this year.

Despite the difficulties that Covid-19 brought to the business environment, Hemofarm also managed to place 17 new products on the market, such as a medicine for the treatment of moderate to severe acute and chronic pain in adults (tapentadol molecule), and a state-of-the-art medicine for osteoporosis patients, a biosimilar teriparatide. Midol Protect 75, Probiotic Daily, Magnetrans Duo are just some of the new products in the company's portfolio.

During the state of emergency, Hemofarm paid a 10 percent salary incentive to employees who worked at production sites on a daily basis, and given the consequences that the pandemic leaves not only on people's physical but also mental health, the company implemented a psychological support program for employees together with Hemofarm Foundation. This program included individual interviews with a psychologist, forums and workshops with psychologists, as well as numerous professional texts available on the internal portal.

It is known that Hemofarm regularly helps health and other institutions, and that was especially important during the current pandemic crisis. Stada and Hemofarm donated 150 medical monitors worth about EUR 400,000 to Serbia, Bosnia and Herzegovina and Montenegro, the countries where they have production facilities. At the same time, Hemofarm Foundation supported Šabac and Vršac, cities where the company has production in Serbia, with five million dinars in the fight against coronavirus. In addition, protective equipment worth EUR 20,000 was donated to health workers in 18 primary healthcare centers in B&H.